Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates
Moderna Reports First Quarter Fiscal Year 2021 Financial Results and Provides Business Updates Read full article Oops! SARS-CoV-2 Variant Booster Program Update : Single booster dose of 50 µg of mRNA-1273 or mRNA-1273.351 increased neutralizing titers against SARS-CoV-2 and two Variants of Concern (B.1.351, P.1) in previously vaccinated clinical trial participants TeenCOVE Study Update : Initial analysis of the Phase 2/3 TeenCOVE study of mRNA-1273 showed vaccine efficacy against COVID-19 of 96%; mRNA-1273 was generally well tolerated with no serious safety concerns identified to date 2021 a...